Patents by Inventor Mikkel Jacob Thaning
Mikkel Jacob Thaning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11884686Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.Type: GrantFiled: June 20, 2017Date of Patent: January 30, 2024Assignee: GE HEALTHCARE ASInventors: Andreas Richard Meijer, Mikkel Jacob Thaning, Brian Christopher Bales, Michael James Rishel
-
Publication number: 20230025866Abstract: The present invention provides a novel method for removal of gadolinium ions from a solution comprising gadolinium complexed with DOTA. The method of the invention is relatively straightforward and cost-efficient compared with known methods.Type: ApplicationFiled: December 18, 2020Publication date: January 26, 2023Inventors: Mikkel Jacob Thaning, Andreas Richard Meijer
-
Publication number: 20220354971Abstract: The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator.Type: ApplicationFiled: June 28, 2022Publication date: November 10, 2022Inventors: Mikkel Jacob Thaning, Andreas Richard Meijer
-
Patent number: 11400172Abstract: The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator.Type: GrantFiled: January 24, 2020Date of Patent: August 2, 2022Assignee: GE HEALTHCARE ASInventors: Mikkel Jacob Thaning, Andreas Richard Meijer
-
Patent number: 11186553Abstract: The present invention relates to a method of preparation of formulations of lanthanide metal complexes of macrocyclic chelators which further comprise a small excess of free chelator. The method uses a solid phase-bound scavenger chelator to remove excess lanthanide metal ions, prior to the addition of a defined excess chelator. Also provided is a method of preparation of MRI contrast agents, together with solid-phase bound chelator meglumine salts useful in the methods.Type: GrantFiled: November 27, 2015Date of Patent: November 30, 2021Assignee: GE HEALTHCARE ASInventors: Mikkel Jacob Thaning, Andreas Richard Meijer
-
Patent number: 11110185Abstract: The present invention relates to in vivo imaging and in particular to magnetic resonance imaging (MRI). Provided by the present invention is a pharmaceutical formulation suitable for use in an MRI procedure and which offers advantages over known such formulations. A particular dose of the pharmaceutical formulation of the invention is also envisioned as well as the use of said dose in a method of in vivo imaging. This present invention provides for simultaneous administration of a liver specific agent and a second MR contrast agent that is capable of better/further enhancing the dynamic vascular phase in a patient. The method of the invention has the advantage of simplicity and patient comfort, compared to sequential injections. Furthermore, the method of the invention provides the advantage that it can enable a lower cumulative dose of contrast agents.Type: GrantFiled: November 30, 2016Date of Patent: September 7, 2021Assignee: GE HEALTHCARE ASInventors: Andreas Richard Meijer, Mikkel Jacob Thaning, Paritosh Jayant Dhawale, Salvatore Desena, Paul Alexander Jones, Deirdre Cassidy, Concetta Valeria Gringeri
-
Patent number: 10941124Abstract: The present invention provides methods for the preparation of compounds useful in in vivo therapeutic and diagnostic applications. In particular, the present invention provides a method for the synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and also methods for the preparation of metal chelates of DOTA.Type: GrantFiled: December 19, 2016Date of Patent: March 9, 2021Assignee: GE HEALTHCARE ASInventors: Andreas Richard Meijer, Arne Wang Aabye, Khalid Hussain, Sondre Nilsen, Mikkel Jacob Thaning, Jarle Andre Haugan, Ingvil Gausemel, Nikolai Enes, Silalahi Sumihar
-
Patent number: 10730897Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.Type: GrantFiled: December 21, 2017Date of Patent: August 4, 2020Assignee: GE HEALTHCARE ASInventors: Mikkel Jacob Thaning, Andreas Richard Meijer, Brian Christopher Bales, Michael James Rishel
-
Publication number: 20200155712Abstract: The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator.Type: ApplicationFiled: January 24, 2020Publication date: May 21, 2020Inventors: Mikkel Jacob THANING, Andreas Richard MEIJER
-
Patent number: 10576169Abstract: The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator.Type: GrantFiled: November 27, 2015Date of Patent: March 3, 2020Assignee: GE HEALTHCARE ASInventors: Mikkel Jacob Thaning, Andreas Richard Meijer
-
Publication number: 20200062791Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.Type: ApplicationFiled: December 21, 2017Publication date: February 27, 2020Inventors: Mikkel Jacob THANING, Andreas Richard MEIJER, Brian Christopher BALES, Michael James RISHEL
-
Publication number: 20190233450Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.Type: ApplicationFiled: June 20, 2017Publication date: August 1, 2019Inventors: Andreas Richard MEIJER, Mikkel Jacob THANING, Brian Christopher BALES, Michael James RISHEL
-
Patent number: 10314927Abstract: The present invention relates to a method of preparation of formulations of gadolinium metal complexes of the macrocyclic chelator DOTA, which further comprise a small excess of free DOTA. The method uses controlled conditions such that excess gadolinium is present as a precipitate of gadolinium oxide, with filtration to remove the excess, prior to the addition of a defined excess of DOTA chelator. Also provided is a method of preparation of MRI contrast agents based on Gd-DOTA.Type: GrantFiled: November 27, 2015Date of Patent: June 11, 2019Assignee: GE HEALTHCARE ASInventors: Mikkel Jacob Thaning, Andreas Richard Meijer
-
Publication number: 20180370925Abstract: The present invention provides methods for the preparation of compounds useful in in vivo therapeutic and diagnostic applications. In particular, the present invention provides a method for the synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and also methods for the preparation of metal chelates of DOTA.Type: ApplicationFiled: December 19, 2016Publication date: December 27, 2018Applicant: GE Healthcare ASInventors: Andreas Richard Meijer, Arne Wang Aabye, Khalid Hussain, Sondre Nilsen, Mikkel Jacob Thaning, Jarle Andre Haugan, Ingvil Gausemel, Nikolai Enes, Silalahi Sumihar
-
Publication number: 20180303960Abstract: The present invention relates to in vivo imaging and in particular to magnetic resonance imaging (MRI). Provided by the present invention is a pharmaceutical formulation suitable for use in an MRI procedure and which offers advantages over known such formulations. A particular dose of the pharmaceutical formulation of the invention is also envisioned as well as the use of said dose in a method of in vivo imaging. This present invention provides for simultaneous administration of a liver specific agent and a second MR contrast agent that is capable of better/further enhancing the dynamic vascular phase in a patient. The method of the invention has the advantage of simplicity and patient comfort, compared to sequential injections. Furthermore, the method of the invention provides the advantage that it can enable a lower cumulative dose of contrast agents.Type: ApplicationFiled: November 30, 2016Publication date: October 25, 2018Applicant: GE Healthcare ASInventors: Andreas Richard Meijer, Mikkel Jacob Thaning, Paritosh Jayant Dhawale, Salvatore Desena, Paul Alexander Jones, Deirdre Cassidy, Concetta Valeria Gringeri
-
Patent number: 9884808Abstract: The present invention relates to a process for the preparation of iodinated X-ray contrast agents and in particular to key intermediates thereof. More particularly, the invention relates to a work-up process for preparation of a compound mixture comprising 1-formylamino-3,5-bis(2,3-bis(formyloxy)propan-1-ylcarbamoyl)-2,4,6-trioodobenzene, a key intermediate in the process for preparing Ioforminol. Further, the invention relates to a process for preparing Ioforminol, a contrast agent useful in X-ray imaging.Type: GrantFiled: September 17, 2013Date of Patent: February 6, 2018Assignee: GE Healthcare ASInventors: Mikkel Jacob Thaning, Jr., Andreas Olsson, Christian Glogard
-
Publication number: 20170266304Abstract: The present invention relates to a method of preparation of formulations of lanthanide metal complexes of macrocyclic chelators which further comprise a small excess of free chelator. The method uses a solid phase-bound scavenger chelator to remove excess lanthanide metal ions, prior to the addition of a defined excess chelator. Also provided is a method of preparation of MRI contrast agents, together with solid-phase bound chelator meglumine salts useful in the methods.Type: ApplicationFiled: November 27, 2015Publication date: September 21, 2017Applicant: GE Healthcare ASInventors: Mikkel Jacob Thaning, Andreas Richard Meijer
-
Publication number: 20170258944Abstract: The present invention relates to a method of preparation of formulations of gadolinium metal complexes of the macrocyclic chelator DOTA, which further comprise a small excess of free DOTA. The method uses controlled conditions such that excess gadolinium is present as a precipitate of gadolinium oxide, with filtration to remove the excess, prior to the addition of a defined excess of DOTA chelator. Also provided is a method of preparation of MRI contrast agents based on Gd-DOTA.Type: ApplicationFiled: November 27, 2015Publication date: September 14, 2017Applicant: GE HEALTHCARE ASInventors: Mikkel Jacob Thaning, Andreas Richard Meijer
-
Publication number: 20170258945Abstract: The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator.Type: ApplicationFiled: November 27, 2015Publication date: September 14, 2017Applicant: GE HEALTHCARE ASInventors: Mikkel Jacob Thaning, Andreas Richard Meijer